{
    "biomarker_id": "BB3847-1",
    "biomarker_canonical_id": "BB3847",
    "condition": {
        "recommended_name": {
            "id": "DOID:1612",
            "resource": "Disease Ontology",
            "url": "https://disease-ontology.org/term/DOID:1612",
            "name": "breast cancer",
            "description": "An organ system cancer that originates in the mammary gland."
        },
        "synonyms": [
            {
                "id": "DOID:1612",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:1612",
                "name": "breast tumor",
                "description": ""
            },
            {
                "id": "DOID:1612",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:1612",
                "name": "malignant neoplasm of breast",
                "description": ""
            },
            {
                "id": "DOID:1612",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:1612",
                "name": "malignant tumor of the breast",
                "description": ""
            },
            {
                "id": "DOID:1612",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:1612",
                "name": "mammary cancer",
                "description": ""
            },
            {
                "id": "DOID:1612",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:1612",
                "name": "mammary tumor",
                "description": ""
            },
            {
                "id": "DOID:1612",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:1612",
                "name": "primary breast cancer",
                "description": ""
            },
            {
                "id": "MONDO:0016419",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0016419",
                "name": "hereditary breast carcinoma",
                "description": "Breast carcinoma that has developed in relatives of patients with history of breast carcinoma."
            },
            {
                "id": "MONDO:0016419",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0016419",
                "name": "breast cancer susceptibility, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0016419",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0016419",
                "name": "breast cancer, early-onset, susceptibility to, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0016419",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0016419",
                "name": "breast cancer, invasive ductal, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0016419",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0016419",
                "name": "breast cancer, lobular, somatic",
                "description": ""
            },
            {
                "id": "MONDO:0016419",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0016419",
                "name": "breast cancer, male, susceptibility to, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0016419",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0016419",
                "name": "breast cancer, protection against, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0016419",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0016419",
                "name": "breast cancer, somatic",
                "description": ""
            },
            {
                "id": "MONDO:0016419",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0016419",
                "name": "breast cancer, susceptibility to, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0016419",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0016419",
                "name": "familial breast cancer",
                "description": ""
            },
            {
                "id": "MONDO:0016419",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0016419",
                "name": "familial breast carcinoma",
                "description": ""
            },
            {
                "id": "MONDO:0016419",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0016419",
                "name": "familial cancer of breast",
                "description": ""
            },
            {
                "id": "MONDO:0016419",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0016419",
                "name": "familial cancer of the breast",
                "description": ""
            },
            {
                "id": "MONDO:0016419",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0016419",
                "name": "hereditary breast cancer",
                "description": ""
            },
            {
                "id": "MONDO:0016419",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0016419",
                "name": "hereditary breast carcinoma",
                "description": ""
            },
            {
                "id": "MIM:114480",
                "resource": "MIM",
                "url": "https://www.omim.org/entry/114480",
                "name": "Breast cancer",
                "description": "Breast cancer"
            }
        ],
        "id": "DOID:1612"
    },
    "biomarker_component": [
        {
            "biomarker": "increased level of Neu5Gc on MUC1",
            "assessed_biomarker_entity_id": "P15941-1",
            "assessed_entity_type": "protein",
            "assessed_biomarker_entity": {
                "recommended_name": "Mucin-1",
                "synonyms": [
                    {
                        "synonym": "Polymorphic epithelial mucin"
                    },
                    {
                        "synonym": "PEM"
                    },
                    {
                        "synonym": "Krebs von den Lungen-6"
                    },
                    {
                        "synonym": "KL-6"
                    },
                    {
                        "synonym": "Tumor-associated epithelial membrane antigen"
                    },
                    {
                        "synonym": "EMA"
                    },
                    {
                        "synonym": "Peanut-reactive urinary mucin"
                    },
                    {
                        "synonym": "PUM"
                    },
                    {
                        "synonym": "Cancer antigen 15-3"
                    },
                    {
                        "synonym": "CA 15-3"
                    },
                    {
                        "synonym": "Tumor-associated mucin"
                    },
                    {
                        "synonym": "MUC1-CT"
                    },
                    {
                        "synonym": "Breast carcinoma-associated antigen DF3"
                    },
                    {
                        "synonym": "PEMT"
                    },
                    {
                        "synonym": "Episialin"
                    },
                    {
                        "synonym": "Carcinoma-associated mucin"
                    },
                    {
                        "synonym": "H23AG"
                    }
                ]
            },
            "specimen": [
                {
                    "name": "blood serum",
                    "namespace": "UBERON",
                    "id": "0001977",
                    "url": "http://purl.obolibrary.org/obo/UBERON_0001977",
                    "loinc_code": ""
                }
            ],
            "evidence_source": [
                {
                    "id": "BB3847-1",
                    "database": "BiomarkerKB",
                    "url": "https://biomarkerkb.org/biomarker/BB3847-1"
                },
                {
                    "id": "40148706",
                    "database": "PubMed",
                    "url": "",
                    "tags": [
                        "assessed_biomarker_entity_id",
                        " assessed_biomarker_entiy",
                        " assessed_entity_type",
                        " biomarker",
                        " specimen"
                    ],
                    "evidence_list": [
                        {
                            "evidence": "A genetically engineered lectin (SubB2M) that specifically binds N-glycolylneuraminic acid (Neu5Gc) was used as a detection reagent in a CA15-3 capture antibody-lectin sandwich (neuCA15-3) assay. Classification accuracy and AUC for neuCA15-3 were 81% and 0.886\u2009\u00b1\u20090.015 (standard error, n\u2009=\u2009567) and for Elecsys CA15-3 II, 55% and 0.642\u2009\u00b1\u20090.023 (n\u2009=\u2009558), respectively. At a threshold cut-off serum concentration of 23.6 units/ml, overall breast cancer classification accuracy of the neuCA15-3 was 81% (compared to 55% for the comparator assay, p\u2009<\u20090.001). The diagnostic performance of neuCA15-3 was substantially improved by specifically targeting both a CA15-3 protein epitope and a pan-cancer glycan (Neu5Gc) epitope (the specific binding target of SubB2M). The reporter signal generated depends on the colocalization of the cancer antigen protein epitope and the aberrant sialylation of the protein, thus increasing the assay specificity. The presence of multiple Neu5Gc lectin-binding sites per glycoprotein molecule increases signal generation and assay sensitivity."
                        }
                    ]
                }
            ]
        }
    ],
    "best_biomarker_role": [
        {
            "role": ""
        }
    ],
    "evidence_source": [
        {
            "id": "BB3847-1",
            "database": "BiomarkerKB",
            "url": "https://biomarkerkb.org/biomarker/BB3847-1"
        },
        {
            "id": "40148706",
            "database": "PubMed",
            "url": "",
            "tags": [
                "condition"
            ],
            "evidence_list": [
                {
                    "evidence": "A genetically engineered lectin (SubB2M) that specifically binds N-glycolylneuraminic acid (Neu5Gc) was used as a detection reagent in a CA15-3 capture antibody-lectin sandwich (neuCA15-3) assay. Classification accuracy and AUC for neuCA15-3 were 81% and 0.886\u2009\u00b1\u20090.015 (standard error, n\u2009=\u2009567) and for Elecsys CA15-3 II, 55% and 0.642\u2009\u00b1\u20090.023 (n\u2009=\u2009558), respectively. At a threshold cut-off serum concentration of 23.6 units/ml, overall breast cancer classification accuracy of the neuCA15-3 was 81% (compared to 55% for the comparator assay, p\u2009<\u20090.001). The diagnostic performance of neuCA15-3 was substantially improved by specifically targeting both a CA15-3 protein epitope and a pan-cancer glycan (Neu5Gc) epitope (the specific binding target of SubB2M). The reporter signal generated depends on the colocalization of the cancer antigen protein epitope and the aberrant sialylation of the protein, thus increasing the assay specificity. The presence of multiple Neu5Gc lectin-binding sites per glycoprotein molecule increases signal generation and assay sensitivity."
                }
            ]
        }
    ],
    "crossref": [
        {
            "id": "BB3847-1",
            "database": "BiomarkerKB",
            "url": "https://biomarkerkb.org/biomarker/BB3847-1",
            "categories": [
                "Biomarkers"
            ]
        }
    ],
    "citation": [],
    "section_stats": [
        {
            "table_id": "biomarker_component",
            "table_stats": [
                {
                    "field": "total",
                    "count": 1
                }
            ],
            "sort_fields": [
                "biomarker",
                "assessed_biomarker_entity_id",
                "assessed_entity_type",
                "assessed_biomarker_entity.recommended_name"
            ]
        },
        {
            "table_id": "citation",
            "table_stats": [
                {
                    "field": "total",
                    "count": 0
                }
            ],
            "sort_fields": []
        }
    ]
}